

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW



Regulated Information

EXERCISE OF THE OVER-ALLOTMENT OPTION AND END OF THE STABILISATION PERIOD IN RELATION TO THE INITIAL PUBLIC OFFERING

Liège, Belgium, 30 July 2015 -17.45 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a pharmaceutical company focused on women’s health, today announces the exercise of the over-allotment option and the end of the stabilisation period, in relation to its initial public offering (the “Offering”).

The Company had granted to ING Belgium SA/NV, as stabilisation manager (the “Stabilisation Manager”), on behalf of ING Belgium SA/NV and KBC Securities NV an over-allotment option to subscribe for up to 903,571 additional new shares at the offer price of EUR 12.00, to cover over-allotments or short positions as a result of over-allotments in connection with the Offering, which was exercisable for a period of 35 calendar days as from the first day of trading of the shares on the regulated market of Euronext Brussels (i.e. 30 June 2015).

The Stabilisation Manager, on behalf of ING Belgium SA/NV and KBC Securities NV has chosen to exercise the over-allotment option for 586,764 new shares, raising additional gross proceeds for the Company of EUR 7.0 million.

As a result, the total number of shares issued in the Offering finally amounts to 6,610,573, representing total gross proceeds of EUR 79.3 million.

After the exercise of the over-allotment option, the share capital of Mithra is represented by 31,129,756 shares. For an overview of the dilution resulting from the Offering, see the section "Principal Shareholders" of the prospectus (the "Prospectus") that has been prepared by the Company in connection with the Offering and that is available on the Company's website (www.mithra.com).

The stabilisation period commenced on 30 June 2015 and ended on 30 July 2015.

In accordance with article 9(3) of EU Regulation No 2273/2003 and article 5, §2 of the Belgian Royal Decree of 17 May 2007, ING Belgium SA/NV, as stabilisation manager, reports the details of the stabilisation activity carried out in appendix A.

For more information, please contact:

Julie Dessart

Head of Communications

+32 4 349 28 22

+32 475 86 41 75

jdessart@mithra.com

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

Jean-Manuel Fontaine

Public Relations

+32 4 349 28 32

+32 476 96 54 59

jmfontaine@mithra.com

François Fornieri, CEO/ Steven Peters, CFO

+32 4 349 28 22

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on women's health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

Appendix A

Day of stabilisation trades	Price range of stabilisation trades (EUR)	# of shares purchased
30/06/15	11.950 - 11.950	85,210
01/07/15	12.000 - 12.000	27,328
02/07/15	12.000 - 12.000	8,175
06/07/15	12.000 - 12.000	10,000
07/07/15	11.660 - 11.750	9,757
08/07/15	11.405 - 11.700	14,687
09/07/15	11.630 - 11.825	10,000
10/07/15	11.935 - 11.960	10,000
13/07/15	11.780 - 11.950	10,000
14/07/15	11.900 - 11.990	20,000
15/07/15	11.880 - 12.000	19,359
16/07/15	11.850 - 12.000	19,227
17/07/15	11.900 - 12.000	8,880
20/07/15	11.940 - 12.000	4,584
21/07/15	11.790 - 11.980	30,000
22/07/15	11.760 - 11.960	13,600
23/07/15	11.930 - 11.940	2,000
24/07/15	11.900 - 11.920	3,000
27/07/15	11.730 - 11.900	5,000
28/07/15	11.770 - 11.900	3,000
29/07/15	11.780 - 11.850	3,000

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

Important information

The information contained in this announcement is for general information only and does not purport to be full or complete. This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares, and any purchase of, subscription for or application for, shares in the Company to be issued in connection with the Offering should only be made on the basis of information contained in the prospectus in connection with the Offering and any supplements thereto, as the case may be. This announcement is not a prospectus. The prospectus contains detailed information about the Company and its management, risks associated with investing in the Company, as well as financial statements and other financial data.

These materials are not for distribution, directly or indirectly, in or into the United States. These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the Offering of the shares in the United States, and does not intend to conduct a public offering of securities in the United States. Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company and that would contain detailed information about the Company and management, as well as financial statements.

This announcement is only addressed to and directed at persons in member states of the European Economic Area ("EEA") other than Belgium who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the relevant Member State of the European Economic Area) and any implementing measure in each relevant Member State of the EEA (the "Prospectus Directive") ("Qualified Investors"). In addition, in the United Kingdom, this announcement is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") and Qualified Investors falling within Article 49(2)(a) to (d) of the Order, and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). The Offering, as the case may be, will only be available to, and any invitation, offer or agreement to subscribe for, purchase, or otherwise acquire securities will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

This announcement and the information contained herein are not for publication, distribution or release in, or into, the United States, Australia, Canada, or Japan.

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends",

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

"may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Acquiring investments to which this announcement relates may expose an investor to a significant risk of losing the entire amount invested. Persons considering such investments should consult an authorised person specialising in advising on such investments. This announcement does not constitute a recommendation concerning the Offering. The value of the shares can decrease as well as increase.

No announcement or information regarding the Offering, as the case may be, or shares referred to above may be disseminated to the public in jurisdictions outside of Belgium where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the Offering or shares of the Company in any jurisdiction outside of Belgium where such steps would be required. The issue, the subscription for or purchase of shares of the Company are subject to special legal or statutory restrictions in certain jurisdictions. The Company is not liable if the aforementioned restrictions are not complied with by any person.

ING Belgium SA/NV and KBC Securities NV are acting for the Company and no one else in relation to the Offering, and will not be responsible to anyone other than the Company for providing the protections offered to their respective clients nor for providing advice in relation to the Offering.

The Company assumes responsibility for the information contained in this announcement. None of ING Belgium SA/NV and KBC Securities NV or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company and its respective subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of announcement or its contents or otherwise arising in connection therewith.